Effect of combination therapy of ruthenium polypyridyl complex, [Ru(dppz)2(PIP)]2+ and parp inhibitors against several cancer cell lines
Ruthenium polypyridyl complexes (RPCs) have been clinically studied as promising anticancer agents in the last decades. The RPC, [Ru(dppz)2(PIP)]2+ or RuPIP where dppz = dipyrido[3,2-a:2’,3’-c]phenazine and PIP = 2-(pheny)- imidazo[4,5-f][1,10]phenantroline has demonstrated anticancer properties...
| 第一著者: | |
|---|---|
| フォーマット: | 学位論文 |
| 言語: | 英語 |
| 出版事項: |
2020
|
| 主題: | |
| オンライン･アクセス: | http://psasir.upm.edu.my/id/eprint/91952/1/FS%202020%2023%20-%20IR.pdf |